Rival CAR-T therapies offer impressive improvements in LBCL

US pharma major Bristol Myers Squibb (NYSE: BMY) has announced the first disclosure of results from a prespecified interim analysis of the pivotal TRANSFORM study at the American Society of Hematology (ASH) Annual Meeting.

The Phase III study evaluating Breyanzi (lisocabtagene maraleucel; liso cel), a CD19-directed CAR-T cell therapy, as a second-line treatment in adults with relapsed or refractory large B-cell lymphoma (LBCL) compared to the standard of care consisting of salvage chemotherapy followed by high-dose chemotherapy plus autologous hematopoietic stem cell transplant (HSCT).

Results show, at a median follow up of 6.2 months, that Breyanzi significantly improved event-free survival (EFS) compared to standard of care, the study’s primary endpoint, with a median EFS of 10.1 months for the BMS drug and 2.3 months for standard of care.